Details

Autor(en) / Beteiligte

• Bush, Karen
• Macielag, Mark J

Titel

New β-lactam antibiotics and β-lactamase inhibitors

Ist Teil von

• Expert opinion on therapeutic patents, 2010-10, Vol.20 (10), p.1277-1293

Ort / Verlag

England: Informa UK, Ltd

Erscheinungsjahr

2010

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Importance of the field: β-Lactam antibiotics are among the most frequently prescribed antibiotics used to treat bacterial infections. However, their utility is being threatened by the worldwide proliferation of β-lactamases with broad hydrolytic capabilities, especially in multidrug-resistant Gram-negative bacteria. Areas covered in this review: This review describes new β-lactams and β-lactamase inhibitors described in the patent literature primarily between 2007 and 2010, together with supportive meeting abstracts and relevant descriptive literature. What the reader will gain: Readers will learn which classes of β-lactam antibiotics are being explored as the most promising groups of compounds to counteract resistance in Gram-negative pathogenic bacteria. Somewhat surprisingly, few traditional β-lactam classes such as penicillins or cephalosporins were described in the literature, other than in combinations with other β-lactams or β-lactamase inhibitors that are being developed to inhibit enzymes from all molecular classes. Take home message: β-Lactam antibiotics are currently being developed as monotherapy by only a few companies. The major emphasis in the past 4 years has been the discovery of novel β-lactamase inhibitors or inhibitor combinations that will allow use of β-lactams against multidrug-resistant bacteria. The use of β-lactams as single agents appears to be a limited option for the future.